Vaxart appoints Dr. James Breitmeyer to board of directors

Vaxart, Inc.

Dr. James Breitmeyer appointed to Vaxart Board effective April 23, 2026.
Brings over 35 years biopharma experience; led programs yielding 8 FDA product approvals.
Currently CEO and director of Altay Therapeutics; formerly President & CEO of Oncternal Therapeutics (2016-2025).
Prior roles include President of Bavarian Nordic (cancer/infectious disease vaccines) and senior clinical leadership at Eli Lilly and Cadence.
Will receive standard non-employee director cash and equity compensation under Vaxart's program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.